Top Markets
Coin of the day
Oscotec Inc. Oscotec Inc.

Oscotec Inc.

039200
주식 순위 #9790
Oscotec Inc. is a biopharmaceutical company specializing in the discovery and... Oscotec Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutic drugs. Its primary focus lies in advancing a pipeline of investigational medicines, including a SYK inhibitor currently in Phase IIa clinical trials for the treatment of both rheumatoid arthritis and immune thrombocytopenia. Another key asset is an FLT3 inhibitor, undergoing Phase I clinical evaluation for acute myeloid leukemia. The company is also developing an EGFR double mutation inhibitor aimed at non-small cell lung cancer, and an Anti-Tau antibody in the preclinical stage for Alzheimer's disease. Beyond its pharmaceutical endeavors, Oscotec Inc. diversifies its offerings with a range of dental health products, such as bone graft materials like InduCera, BioCera-F, and SynCeraII, alongside membranes including LysoGide and CollaGuide. Additionally, it markets functional ingredients designed to address specific health concerns, such as OPB for osteoporosis, AIF for arthritis, SGA for enhancing bone growth, and PRF-K for periodontal conditions. Established in 1988, the company, originally known as Oscotec Co., Ltd, adopted its current name, Oscotec Inc., in June 1999. It is headquartered in Seongnam, South Korea.
주가
$24.76
마지막 동기화: 2026-08-28
시가총액
$947.10M
변동 (1일)
2.14%
변동 (1년)
-6.44%
국가
KR
거래 Oscotec Inc. (039200)

카테고리

Oscotec Inc. (039200)의 수익
2026 기준 수익 TTM: 0
Oscotec Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Oscotec Inc.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$33.59B -
US
$25.20B -
US
$8.70B -
US
$21.39B -
CH
$5.95B -
US